Preview

Rational Pharmacotherapy in Cardiology

Advanced search

According to the AUGUSTUS Trial Apixaban (Eliquis ® ) was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention

Full Text:

Abstract

Pfizer Company Press Release.

About the Author

Company Pfizer

Russian Federation


References

1. Peterson ED, Pokorney SD. New Treatment Options Fail to Close the Anticoagulation Gap in Atrial Fibrillation. Journal of the American College of Cardiology. 2017;69(20).

2. The AFFIRM Investigators. Baseline characteristics of patients with atrial fibrillation: the AFFIRM study. American Heart Journal. 2002; 143: 991-1001.

3. Capodanno, D., Angiolillo, DJ. Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. Circulation: Cardiovascular Interventions. 2014;7:133-124.

4. Rubboli A, Colletta, M, Herzfeld J, et al. Periprocedural and medium-term antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary angiography and intervention. Coronary Artery Disease. 2007;18:193-199.

5. Wang TY, Robinson LA, Ou FS et al. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. American Heart Journal. 2008;155:361-8.

6. Perez-Gomez F, Alegria E, Berjon J, et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. Journal of the American College of Cardiology. 2004;44:1557-66.

7. Lip GY, Huber K, Andreotti, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thrombosis and Haemostasis. 2010;103:13-28.


For citation:


According to the AUGUSTUS Trial Apixaban (Eliquis ® ) was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention. Rational Pharmacotherapy in Cardiology. 2019;15(4):604-606. (In Russ.)

Views: 57


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)